Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM – PR Newswire

  • Israel Lowy,

Press/Media

Period12 Sep 2022

Media coverage

21

Media coverage